Proliferative Vitreoretinopathy Market

Market Overview:

The 7 major proliferative vitreoretinopathy markets reached a value of US$ 1.7 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 4.1 Billion by 2034, exhibiting a growth rate (CAGR) of 8.45% during 2024-2034.

The proliferative vitreoretinopathy market has been comprehensively analyzed in IMARC's new report titled "Proliferative Vitreoretinopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Proliferative vitreoretinopathy is a condition that impairs the retina, which is the light-sensitive covering of tissue at the back of the eye. This disease occurs when cells within the retina grow and multiply abnormally, causing scar tissue that results in vision loss or blindness. The severity of symptoms can vary greatly depending on the scar tissues' extent and location. Individuals suffering from the ailment may experience visual problems, including floaters or flashes of light, peripheral (side) or central loss of vision, reduced visual field, decreased visual acuity, sensitivity to light, etc. The diagnosis of the disease typically requires a combination of in-depth patient history and clinical features. Physical examination and medical history can provide detailed information on the disease frequency and duration, as well as any associated health conditions. The healthcare provider may also perform a dynamic ultrasound examination, which can detect the presence of retinal detachment, along with specific characteristics of proliferative vitreoretinopathy, to confirm a diagnosis.

The increasing cases of eye trauma, retinal detachment, surgical manipulations, etc., which trigger a reactive process of the ocular tissue against cytokines and inflammatory mediators, are primarily driving the proliferative vitreoretinopathy market. Moreover, the rising prevalence of various associated risk factors, such as a smoking history, complicated cataract surgery, a large retinal tear, diabetes, severe nearsightedness, etc., is also bolstering the market growth. Besides this, the escalating utilization of scleral buckling surgery for the treatment of proliferative vitreoretinopathy is acting as another significant growth-inducing factor. This operation involves the placement of a silicone rubber or sponge piece outside the eyeball to support the retina for complete healing, thereby improving the quality of life for patients. Furthermore, the growing application of colchicine and taxol, which respectively inhibit and stabilize microtubule formation to reduce migration and proliferation of cells, is also positively influencing the market. Apart from this, the emerging popularity of the intravitreal formulation of methotrexate owing to its several benefits, including being vitreous-compatible and having an optimized administration volume, is expected to drive the proliferative vitreoretinopathy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the proliferative vitreoretinopathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for proliferative vitreoretinopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the proliferative vitreoretinopathy market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the proliferative vitreoretinopathy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the proliferative vitreoretinopathy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current proliferative vitreoretinopathy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the proliferative vitreoretinopathy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2034?
• What was the country-wise size of the proliferative vitreoretinopathy market across the seven major markets in 2024 and what will it look like in 2034?
• What is the growth rate of the proliferative vitreoretinopathy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of proliferative vitreoretinopathy across the seven major markets?
• What is the number of prevalent cases (2018-2034) of proliferative vitreoretinopathy by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of proliferative vitreoretinopathy by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with proliferative vitreoretinopathy across the seven major markets?
• What is the size of the proliferative vitreoretinopathy patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of proliferative vitreoretinopathy?
• What will be the growth rate of patients across the seven major markets?
   

Proliferative Vitreoretinopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for proliferative vitreoretinopathy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the proliferative vitreoretinopathy market?
• What are the key regulatory events related to the proliferative vitreoretinopathy market?
• What is the structure of clinical trial landscape by status related to the proliferative vitreoretinopathy market?
• What is the structure of clinical trial landscape by phase related to the proliferative vitreoretinopathy market?
• What is the structure of clinical trial landscape by route of administration related to the proliferative vitreoretinopathy market?